Portfoliotracker

ProQR Therapeutics N.V.

PRQR · NASDAQCM · Healthcare Biotechnology 30/100 E

1,180 $
▼ −0,230 (−16,31 %)
Pre-market delayed by 15 min
Price as of 16. 11. 22:00, fetched 17. 11. 13:58
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score30 / 100 Market cap167 mil. $ P/E– Forward P/E-2,5 P/S9,1 P/B1,9 EV/EBITDA-2,2 Dividend yield– FCF yield– EPS-0,45 $ Net margin-228,2 % Return on equity-57,4 % Beta0,27 Debt / equity0,19
52-week range 1,18 to 2,49
3-month average volume0,8 M

We do not have financial statements yet

The company reports in EUR, while the price is quoted in USD. We do not convert statements between currencies yet, because the multiples (P/E, P/S and others) would come out wrong, so we do not show them here. You can see the price and its history above.

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metabolic dysfunction-associated steatohepatitis; and AX-1412, which targets the B4GALT1 gene for cardiovascular diseases. It has a research and collaboration agreement with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Website
proqr.com
Employees
186
Country
Netherlands
Data since
18. 9. 2014

Explore further

Similar companies CTMXWVE

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account